salmeterol xinafoate has been researched along with Asthma, Bronchial in 6 studies
salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, AD | 2 |
| Bunnage, ME | 2 |
| Glossop, PA | 2 |
| Holbrook, M | 1 |
| Jones, RD | 1 |
| Lane, CA | 2 |
| Lewthwaite, RA | 2 |
| Mantell, S | 1 |
| Perros-Huguet, C | 2 |
| Price, DA | 2 |
| Webster, R | 2 |
| James, K | 1 |
| Yeadon, M | 1 |
| Trevethick, MA | 1 |
| Clarke, NP | 1 |
| Jones, RM | 1 |
| Burrows, JL | 1 |
| Feeder, N | 1 |
| Taylor, SC | 1 |
| Spence, FJ | 1 |
| Alcaraz, L | 1 |
| Bailey, A | 1 |
| Cadogan, E | 1 |
| Connolly, S | 1 |
| Jewell, R | 1 |
| Jordan, S | 1 |
| Kindon, N | 1 |
| Lister, A | 1 |
| Lawson, M | 1 |
| Mullen, A | 1 |
| Dainty, I | 1 |
| Nicholls, D | 1 |
| Paine, S | 1 |
| Pairaudeau, G | 1 |
| Stocks, MJ | 1 |
| Thorne, P | 1 |
| Young, A | 1 |
| Jacobsen, JR | 2 |
| Choi, SK | 1 |
| Combs, J | 1 |
| Fournier, EJ | 1 |
| Klein, U | 2 |
| Pfeiffer, JW | 2 |
| Thomas, GR | 2 |
| Yu, C | 2 |
| Moran, EJ | 2 |
| McKinnell, RM | 1 |
| Linsell, MS | 1 |
| Nodwell, MB | 1 |
| Xing, G | 1 |
| Woo, AY | 1 |
| Pan, L | 1 |
| Lin, B | 1 |
| Cheng, MS | 1 |
1 review available for salmeterol xinafoate and Asthma, Bronchial
| Article | Year |
|---|---|
Recent Advances in β
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Heart Failure; Humans; Muscle | 2020 |
5 other studies available for salmeterol xinafoate and Asthma, Bronchial
| Article | Year |
|---|---|
The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Biological Availability; Caco-2 Cells; CHO Cel | 2007 |
Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; | 2010 |
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.
Topics: Adrenergic beta-Agonists; Animals; Asthma; Bronchodilator Agents; Cell Line, Tumor; Chemistry, Pharm | 2012 |
A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Anti-Asthmatic Agents; Asthma; Cell Line; Drug Discove | 2012 |
Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Cell Line; Diphenylamine; Disease Models, Anim | 2014 |